在中度至重度喘中使用单个吸入器三重疗法的现实有效性和安全性:TriMaximize研究
Christian Gessner1,2, Richard E K Russell3, Timm Greulich4
1Pulmonary Practice/ Medical S/P/E, Leipzig, Germany.
Journal of asthma and allergy
|March 2, 2026
概括
现实数据显示,额外精细贝克洛美塔松二二/形式醇烟酸/葡萄糖 (BDP/FF/G) 显著改善了喘控制和生活质量. 这种三重疗法减少了中度至重度喘患者的全身皮质类固醇使用和恶化.
科学领域:
- 呼吸系统医学 呼吸系统医学
- 临床药理学 临床药理学
- 现实世界的证据.
背景情况:
- 喘仍然是一个重大的全球健康负担,需要有效和安全的治疗策略.
- 用吸入性皮质类固醇,长效β-激动剂和长效肌酸抗剂的三重治疗提供了一种全面的方法来管理中度至重度喘.
- 吸入药物的超细配方增强了肺部沉积,并可能改善治疗结果.
研究的目的:
- 为了前性地收集对中度至重度喘患者的真实世界数据,这些患者接受了额外精细单次吸入剂贝克洛马二 propionate/formoterol fumarate/glycopyrronium (BDP/FF/G) 的治疗.
- 评估患者的特征,治疗途径和与36个月的中高强度BDP/FF/G疗法相关的结果.
- 在一个跨国队列中评估喘控制,与健康相关的生活质量和肺功能.
主要方法:
- TriMaximize研究是一项非干预性,前性,多中心试验,在八个欧洲国家进行.
- 在2021年至2024年期间,成人患者中度至重度的喘开始BDP/FF/G (中度或高强度) 被招募.
- 收集的数据包括人口统计,临床特征,肺功能测试,喘控制 (喘控制测试 - ACT),与健康有关的生活质量 (迷你喘生活质量问卷 - Mini-AQLQ) 和治疗途径.
主要成果:
- 包括1445名患者,其中大多数患者从固定剂量组合吸入器过渡.
- 在研究期间,87.1%的患者仍在使用BDP/FF/G. 系统性皮质类固醇使用 (33.2%至12.4%) 和救援药物使用的显著减少.
- 在喘控制 (ACT分数) 和生活质量 (Mini-AQLQ分数) 中报告了临床上有意义的改善,以及FEV1.1的增加. 实现了高临床缓解率.
结论:
- 额外的,单次吸入器BDP/FF/G疗法在中度至重度喘的现实临床实践环境中证明了有效性和安全性.
- 这项研究支持这种三重疗法在减少恶化和改善患者报告结果方面具有实用性.
- 这些发现凸显了BDP/FF/G在日常护理中管理一系列中度至重度喘患者的好处.
相关概念视频
Asthma-IV: Diagnostic and Management
3.2K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K
Antiasthma Drugs: β2-Adrenoceptor Agonists
1.9K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.9K
Antiasthma Drugs: Methylxanthines
1.8K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.8K
Inhaled Medications
916
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
916
Antiasthma Drugs: Leukotriene Modifiers
2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.0K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.1K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K


